Cerezyme 400 Units Powder for concentrate for solution for infusion
Sponsors
Genzyme Corp., Sanofi-Aventis Recherche & Developpement
Conditions
Gaucher's disease type I; Gaucher's disease type IIIGaucher's disease type III
Phase 3
Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3
CompletedCTIS2024-510751-34-00
Start: 2019-03-26End: 2025-12-23Target: 23Updated: 2025-12-04
LEAP2MONO - EFC17215 A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 (GD3) who have reached therapeutic goals with Enzyme Replacement Therapy (ERT)
Active, not recruitingCTIS2024-514381-39-00
Start: 2022-12-08Target: 15Updated: 2025-11-14